Auris Medical Holding AG (NASDAQ:EARS) shares fell 11.7% on Thursday . The stock traded as low as $0.49 and last traded at $0.53. 2,215,162 shares changed hands during trading, an increase of 23% from the average session volume of 1,805,321 shares. The stock had previously closed at $0.60.

Separately, Zacks Investment Research lowered shares of Auris Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th.

The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of -14.04.

An institutional investor recently bought a new position in Auris Medical stock. Virtu KCG Holdings LLC bought a new position in shares of Auris Medical Holding AG (NASDAQ:EARS) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned 0.32% of Auris Medical as of its most recent filing with the SEC. 25.15% of the stock is currently owned by institutional investors.

WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/auris-medical-ears-stock-price-down-11-7/1797233.html.

Auris Medical Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with Analyst Ratings Network's FREE daily email newsletter.